 Synthetic peptide inhibitors of HIV transmission |
| OF THE INVENTION 5.1 DP-178 AND DP-178-LIKE PEPTIDES 5.2 ASSAYS FOR ANTIVIRAL ACTIVITY 5.3 USES OF ... |
|
| Compounds which inhibit HIV replication |
| A first aspect of the present invention is a peptide selected from the group consisting of: (a) the ... |
|
| Hybrid polypeptides with enhanced pharmacokinetic properties |
| OF THE INVENTION Described herein are peptide sequences, referred to as enhancer peptide sequences,... |
|
| 1-aryl-2-hydroxyethyl amides as potassium channel openers |
| OF THE INVENTION The present invention provides novel aryl hydroxyethyl amides and related ... |
|
| Method of eliciting anti-HIV-1 helper T cell responses |
| A number of HIV-1 p24 peptides that elicit HIV-1-specific helper T cell responses have been ... |
|
| pDJA1, a cardiac specific gene, corresponding proteins, and uses thereof |
| OF THE INVENTION Before the present methods and treatment methodology are described, it is to be ... |
|
| GPIb.alpha. fragments and recombinant DNA expression vectors |
| As set forth in aforementioned application Ser. No. 07/470,674, there are provided peptides ... |
|
| Expression vector encoding hybrid immunoglobulins |
| Ligand binding partners as defined herein are proteins known to function to bind specifically to ... |
|
| Hybrid immunoglobulins |
| Ligand binding partners as defined herein are proteins known to function to bind specifically to ... |
|
| GPIb-lipid complex and uses thereof |
| What is claimed is: 1. A complex comprising a lipid and a conjugate of GPIb or a GPIB fragment ... |
|
|
Modulation of cholesteryl ester transfer protein (CETP) activity
| Details |
Inventors: Rittershaus, Charles W.; Thomas, Lawrence J.;
Assignee: Avant Immunotherapeutics, Inc. (Needham, MA)
Primary Examiner: Chan; Christina
Assistant Examiner: Belyavskyi; Michail
Attorney, Agent or Firm: Yankwich; Leon R. O'Brien; David G. Yankwich & Associates P.C.
This invention relates to peptides comprising a helper T cell epitope portion and a B cell epitope portion for eliciting an immune response against endogenous cholesteryl ester transfer protein (CETP) activity, to prevent or treat cardiovascular disease, such as atherosclerosis. |
|
DETAILED DESCRIPTION The invention claimed is: 1.
A method for treating or preventing atherosclerosis in a human or animal comprising administering to said human or animal an antigenic vaccine peptide comprising a universal helper T cell epitope portion linked to a B cell epitope portion, wherein said B cell epitope portion comprises a B cell epitope of CETP.
2.
The method according to claim 1, wherein said helper T cell epitope portion comprises a helper T cell epitope derived from an antigenic peptide selected from the group consisting of tetanus toxoid, diphtheria toxoid, pertussis vaccine, Bacile Calmette-Guerin (BCG), polio vaccine, measles vaccine, mumps vaccine, rubella vaccine, purified protein derivative of tuberculin, keyhole limpet hemocyanin, hsp70, and combinations thereof.
3.
The method according to claim 1, wherein said B cell epitope portion of the antigenic vaccine peptide comprises 6 to 26 consecutive amino acids of the carboxyl terminal 26 amino acids of human cholesteryl ester transfer protein (SEQ ID NO:1).
4.
The method according to claim 3, wherein the vaccine peptide comprises the amino acid sequence of SEQ ID NO:2.
5.
The method according to claim 3, wherein the vaccine peptide comprises a dimer of the amino acid sequence of SEQ ID NO:2.
6.
The method according to claim 1, wherein the mode of said administration of said antigenic vaccine peptide is selected from the group consisting of intraperitoneal administration, interperitoneal administration, intramuscular injection, intravenous injection, subcutaneous injection, and oral administration.
7.
The method according to claim 6, wherein said administration is comprised of one primary dose of said antigenic vaccine peptide followed by one or more booster administrations of said vaccine peptide.
8.
The method according to claim 1, wherein said antigenic vaccine peptide is formulated with a pharmaceutically acceptable adjuvant.
9.
The method according to claim 8, wherein said pharmaceutically acceptable adjuvant is alum
|
| Related patents |
|
|
Nucleic acids, vectors and host cells encoding heregulin
In accordance with the objects of this invention, we have identified and isolated novel ligand families which bind to p185.sup.HER2. These ligands are denominated the ...
|
|
|
Immunoreactive peptides from Epstein-Barr virus
What is claimed is: 1. A polypeptide consisting of an amino acid sequence having the formula: (.phi.).sub.n wherein n is 1 to about 1000 and .phi. is 25 amino acids or ...
|
|
|
DNA encoding stationary phase, stress response sigma factor from Mycobacterium tuberculosis
OF THE INVENTION It is a discovery of the present invention that entry of M. tuberculosis into a latent state is under the influence of an M. tuberculosis gene encoding ...
|
|
|
Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
The present invention provides, among other things, a method of removing virus from a sample. The method comprises contacting a sample with a composition comprising an ...
|
|
|
.alpha.-.beta. C4BP-type recombinant heteromultimeric proteins
The object of the present invention is therefore to develop recombinant soluble heteromultimeric chimeric molecules which combine different functions in one and the same ...
|
|
|
Semi-refined carrageenan
The present invention provides methods for preparing a carrageenan product comprising the steps of providing a carrageenan-containing seaweed material having a seaweed ...
|
|
|
Method for improving genetic stability of foreign insert nucleotide sequence in recombinant poliovirus
To be free from shortcomings of the poliovirus vector systems, in particular, genetic instability of the foreign insert integrated into the recombinant polioviruses, the ...
|
|
|
Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
The invention relates to adult dedifferentiated programmable stem cells derived from human monocytes, as well as their production and use for the production of body ...
|
|
|
Peptides which enhance transport across tissues and methods of identifying and using the same
The invention provides a method of identifying a peptide which permits or facilitates the transport of an active agent through a human or animal tissue. A predetermined ...
|
|
|
Synthetic peptides and kits for diagnosis of anti-phospholipid syndrome
The invention claimed is: 1. A synthetic peptide selected from the group consisting: (i) a peptide of SEQ ID NO:1 to SEQ ID NO: 7, of the sequences: Leu-Lys-Thr-Pro-Arg-V...
|
|
|
Drugs 
